April 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Daiichi Sankyo Files Application for Dysuria Treatment KMD-3213 in China
 

Tokyo, Jan 8, 2009 (JCN) - Daiichi Sankyo announced today that subsidiary Daiichi Pharmaceutical (Beijing) Co., Ltd. filed an application for KMD-3213 (generic name: silodosin) to China's State Food and Drug Administration (SFDA).

KMD-3213 is a selective alpha 1A-adrenoceptor antagonist developed for treatment of dysuria associated with benign prostatic hyperplasia.

Originally discovered by Kissei Pharmaceutical Co., Ltd., it was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief in Japan.

KMD-3213 has shown efficacy in significantly improving urinary disturbance soon after dosage and is expected to contribute to improving the quality of life in patients.


By Saroj Shrestha Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Daiichi Sankyo  News  
  Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria  (Aug 1, 2013)
  Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy  (Feb 15, 2013)
  Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign  (Dec 20, 2012)
  Daiichi Sankyo, Ranbaxy Launch Psteoporosis Medication EVISTA in Romania  (Sept 2, 2009)
  Daiichi Sankyo Files Application for Dysuria Treatment KMD-3213 in China  (Jan 8, 2009)
  Daiichi Sankyo and Ranbaxy Move Forward Toward The Completion of the Landmark Deal  (Oct 20, 2008)
  Daiichi Sankyo's Tender Offer for Ranbaxy Ends in Success  (Oct 17, 2008)
  Shionogi to Acquire U.S. Drug Maker Sciele Pharma  (Sept 1, 2008)
  Daiichi Sankyo to Buy Indian Drug Giant Ranbaxy  (June 11, 2008)
  Daiichi Sankyo to Acquire German Biomedical Firm  (May 21, 2008)



 Recent  Drugs & OTC News   
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)
Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production (June 24, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)